PURPOSE: presentation by the Commission of the
consolidated annual accounts of the European Union for the
financial year 2013, as part of the 2013 discharge
procedure.
Analysis of the accounts of the Joint Technology
Initiative on Innovative Medicines (IMI).
CONTENT: this Commission document sets out the
consolidated annual accounts of the European Union for the
financial year 2013 as prepared on the basis of the information
presented by the institutions, organisations and bodies of the EU,
in accordance with Article 129 (2) of the Financial Regulation
applicable to the EU's General Budget, including the IMI Joint
Undertaking.
The document contains the figures on which the
discharge procedure is based.
Discharge procedure of the EU Joint
Undertakings: the EU Budget finances
a wide range of policies and programmes throughout the EU. In
accordance with the priorities set by the European Parliament and
the Council in the multi-annual financial framework (MFF), the
European Commission carries out specific programmes, activities and
projects in the field with the technical support of some
specialised agencies.
The consolidated annual accounts of the EU provide
information on the activities of the institutions, agencies and
other bodies of the EU from a budgetary and accrual accounting
perspective.
The consolidated reports on the implementation of the
general budget of the EU include the budget implementation of all
Institutions. Agencies and Joint Undertakings (JUs) do not have
a separate budget inside the EU budget; and they are partially
financed by a Commission budget subsidy.
Each JU is subject to its own discharge
procedure.
IMI: in 2013, the tasks
and budget of the Joint Undertaking were as follows:
- description of the tasks of the Joint
Undertaking: the IMI Joint
undertaking, which is located in Brussels, was set up in 2007 by
Council Regulation (EC) No
73/2008 for a period of 10 years. The IMI Joint
Undertaking supports pre-competitive pharmaceutical research and
development in the Member States and associated countries, aiming
at increasing the research investment in the biopharmaceutical
sector and promotes the involvement of small and medium-sized
enterprises (SME) in its activities;
- accounts of the JU: the
maximum indicative contribution of the Commission to cover running
costs and research activities is EUR 1 billion up to 31.12.2017.
The cumulative unrecognised share of losses is EUR 16
million.
Please also consult the final accounts of IMI Joint
Undertaking.